XNAS · Healthcare · Biotechnology
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -0.32 | -0.19 | +40.62% | $26.5M | ✅ Beat | +0.13% | +11.58% | +29.27% |
| 2026-03-09 | Q4 2025 | -0.22 | -0.24 | -9.09% | $24.1M | ❌ Miss | +2.00% | -13.49% | -15.73% |
| 2025-11-10 |
| Q3 2025 |
| -0.03 |
| 0.18 |
| +700.00% |
| $21.5M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | 0.54 | -0.56 | -203.70% | $119,000 | ❌ Miss | -4.24% | +0.87% | +28.11% |
| 2025-03-27 | Q4 2024 | -0.69 | -0.64 | +7.25% | $212,000 | ✅ Beat | -3.02% | -7.79% | +11.29% |
| 2024-11-20 | Q3 2024 | -10.69 | -8.40 | +21.42% | $176,000 | ✅ Beat | -3.16% | +10.13% | +7.91% |
Showing last 6 quarters.